| Editor's Choice: Policy & Regulations | A bad outcome for Johnson & Johnson MedTech just got worse. A jury previously ordered the company to pay $147M, but the new total is $442M. A bad outcome for Johnson & Johnson MedTech just got worse. A jury previously ordered the company to pay $147M, but the new total is $442M. | | |
| The American Society of Nuclear Cardiology made its voice heard, pushing for legislation to repeal Medicare payment cuts and tie payments to inflationary increases. Prior authorization and a proposed tariff on radioisotopes were also discussed. The American Society of Nuclear Cardiology made its voice heard, pushing for legislation to repeal Medicare payment cuts and tie payments to inflationary increases. Prior authorization and a proposed tariff on radioisotopes were also discussed. | | |
| COVID-19 vaccines are associated with a very low risk of myocarditis and/or pericarditis, primarily in young adults. The long-term impact of this risk has been the subject of many studies and debates over the years. One side says that the benefits of vaccination far outweigh the risks, and the other side says that even the smallest risk of heart damage is too high. COVID-19 vaccines are associated with a very low risk of myocarditis and/or pericarditis, primarily in young adults. The long-term impact of this risk has been the subject of many studies and debates over the years. One side says that the benefits of vaccination far outweigh the risks, and the other side says that even the smallest risk of heart damage is too high. | | |
| "The lead protection we wear is causing a lot of damage," SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, explained in an interview. "The lead protection we wear is causing a lot of damage," SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, explained in an interview. | | |
| Rishi Wadhera, MD, MPP, MPhil, a cardiologist who also specializes in healthcare policy, spoke to Cardiovascular Business about the good, the bad and the unknown when it comes to private equity's role in cardiology. Rishi Wadhera, MD, MPP, MPhil, a cardiologist who also specializes in healthcare policy, spoke to Cardiovascular Business about the good, the bad and the unknown when it comes to private equity's role in cardiology. | | |
| Overall, 30-day outcomes were not significantly different for hospitals after being acquired by a private equity firm. However, the study’s authors did identify trends that suggest there may be a drop in the quality of care. Overall, 30-day outcomes were not significantly different for hospitals after being acquired by a private equity firm. However, the study’s authors did identify trends that suggest there may be a drop in the quality of care. | | |
| Gerald G. Blackwell, MD, MBA, MedAxiom's president and CEO, examined how different cardiology employment models look today compared to even a decade ago. Gerald G. Blackwell, MD, MBA, MedAxiom's president and CEO, examined how different cardiology employment models look today compared to even a decade ago. | | |
| The device was built as a bridge to transplant for patients with end-stage heart failure. It is made of titanium and approximately the size of an adult’s fist. The device was built as a bridge to transplant for patients with end-stage heart failure. It is made of titanium and approximately the size of an adult’s fist. | | |
| SCAI and other healthcare groups want changes made to how healthcare providers are paid after performing office-based lab procedures. "As much as we love delivering care as doctors, if we are losing money doing something, we cannot sustain it," one cardiologist explained. SCAI and other healthcare groups want changes made to how healthcare providers are paid after performing office-based lab procedures. "As much as we love delivering care as doctors, if we are losing money doing something, we cannot sustain it," one cardiologist explained. | | |
| A new surgical mitral valve from Foldax will now be commercially available in India. The valve is built using LifePolymer, a proprietary material that does not include animal tissue. A new surgical mitral valve from Foldax will now be commercially available in India. The valve is built using LifePolymer, a proprietary material that does not include animal tissue. | | |
| |
|
| ![]() | |
|
